About eisai co. ltd. - ESALF
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.
ESALF At a Glance
Eisai Co., Ltd.
4-6-10 Koishikawa
Tokyo, Tokyo 112-8088
| Phone | 81-3-3817-3030 | Revenue | 5.18B | |
| Industry | Pharmaceuticals: Major | Net Income | 304.58M | |
| Sector | Health Technology | 2025 Sales Growth | 0.945% | |
| Fiscal Year-end | 03 / 2026 | Employees | 10,917 | |
| View SEC Filings |
ESALF Valuation
| P/E Current | 26.06 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 25.804 |
| Price to Sales Ratio | 1.518 |
| Price to Book Ratio | 1.39 |
| Price to Cash Flow Ratio | 39.782 |
| Enterprise Value to EBITDA | 13.327 |
| Enterprise Value to Sales | 1.505 |
| Total Debt to Enterprise Value | 0.198 |
ESALF Efficiency
| Revenue/Employee | 474,313.339 |
| Income Per Employee | 27,899.406 |
| Receivables Turnover | 3.527 |
| Total Asset Turnover | 0.56 |
ESALF Liquidity
| Current Ratio | 1.953 |
| Quick Ratio | 1.373 |
| Cash Ratio | 0.713 |
ESALF Profitability
| Gross Margin | 75.657 |
| Operating Margin | 6.238 |
| Pretax Margin | 7.736 |
| Net Margin | 5.882 |
| Return on Assets | 3.296 |
| Return on Equity | 5.338 |
| Return on Total Capital | 4.246 |
| Return on Invested Capital | 4.531 |
ESALF Capital Structure
| Total Debt to Total Equity | 27.474 |
| Total Debt to Total Capital | 21.553 |
| Total Debt to Total Assets | 16.673 |
| Long-Term Debt to Equity | 15.84 |
| Long-Term Debt to Total Capital | 12.426 |